DALLAS, April 16, 2015 /PRNewswire/ --
RnRMarketResearch.com adds 2015 EpiCast Report on Alzheimer's Disease - Epidemiology Forecast to 2023 of 82 pages to the Alzheimer Drugs section of Diseases and Treatments category in its online market research library.
The EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2023 forecasts that by 2023, there will be approximately 17.38 million total prevalent cases of AD across the 9MM covered in this analysis. Epidemiologists expect a 34.3% increase in the total prevalent cases of AD in the 9MM over the next decade. Similarly, epidemiologists forecast that the total prevalent cases of MCI in the 9MM will increase from 82.25 million cases in 2013 to 108.41 million cases in 2013 at a decadal growth rate of 31.80%. Complete research is available at http://www.rnrmarketresearch.com/epicast-report-alzheimers-disease-epidemiology-forecast-to-2023-market-report.html .
This Alzheimer's disease (AD) EpiCast Report provides an overview of the risk factors and global trends of AD in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, China, and India). The series also includes a 10-year epidemiological forecast for the total prevalent cases of AD segmented by sex, age, and severity in these markets. In addition, the report includes a 10-year epidemiological forecast for the total prevalent cases of mild cognitive impairment (MCI) segmented by sex and age in these markets. The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.
To forecast the total prevalent cases of AD in adults ages =60 years in the 9MM during the forecast period (2013-2023), epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-III-R) to diagnose dementia, and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria to diagnose AD. Similarly, to forecast the total prevalent cases of MCI in the 9MM, epidemiologists selected country-specific studies that defined MCI as a "slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills, but no dementia." Additionally, epidemiologists kept the forecast methodology consistent across the 9MM in order to allow for a meaningful comparison of the total prevalent cases between the markets.
AD is an irreversible, neurodegenerative brain disease of the elderly, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity. Similar to AD, mild cognitive impairment (MCI) is also a condition of the elderly in which there is a slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills, but no dementia.
The Epidemiology Forecasts to 2023 chapter of this research covers data and information on Total Prevalent Cases of AD, Age-Specific Total Prevalent Cases of AD, Sex-Specific Total Prevalent Cases of AD, Age-Standardized Total Prevalence of AD, Total Prevalent Cases of AD, by Severity, Total Prevalent Cases of MCI, Age-Specific Total Prevalent Cases of MCI, Sex-Specific Total Prevalent Cases of MCI and Age-Standardized Total Prevalence of MCI. Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=356999 .
Another research of 197 pages on Alzheimer's Disease - Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Companies like AB Science, AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Acelot, Inc., Acumen Pharmaceuticals, Inc., Adamas Pharmaceuticals, Inc., Addex Therapeutics Ltd, AFFiRiS AG, Alector LLC, ALSP, Inc., Alzhyme Pty Ltd, Alzinova AB, AlzProtect SAS, Amarantus Bioscience Holdings, Inc., Amgen Inc., Anavex Life Sciences Corp., Angita B.V., Apodemus AB, Araclon Biotech, S.L., Archer Pharmaceuticals, Inc., ArmaGen Technologies, Inc., Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Ausio Pharmaceuticals, LLC, Avergen Ltd, Avineuro Pharmaceuticals, Inc., Axerion Therapeutics, Inc., Axon Neuroscience SE, Axxam SpA, Azevan Pharmaceuticals, Inc., BioArctic Neuroscience AB, biOasis Technologies Inc., Biogen Idec Inc., Biomar Microbial Technologies, Bionature E.A. Ltd., Biotie Therapies Corp., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Bsim2, CalAsia Pharmaceuticals, Inc., Cardax Pharmaceuticals, Inc., Celon Pharma Sp. z o.o., CHA Bio & Diostech Co., Ltd., Chase Pharmaceuticals Corporation, Clera Inc., Cognition Therapeutics, Inc., Cognosci, Inc., CoLucid Pharmaceuticals, Inc., CoMentis, Inc., Cortica Neurosciences, Inc., Critical Outcome Technologies Inc., CrystalGenomics, Inc., D-Pharm Ltd., Daewoong Pharmaceutical Co., Ltd., Delenex Therapeutics AG, DermaXon, LLC, Domain Therapeutics SA, Echo Pharmaceuticals B.V., Eisai Co., Ltd., and Eli Lilly and Company are discussed in this report available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=308873 .
Explore more reports on other diseases and treatments sector at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
Market Research Blog: http://www.rnrmarketresearch.com/blog/
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
SOURCE RnR Market Research